NR1H4 and metabolic dysfunction-associated steatohepatitis: Collectively, these data suggested that SC treatment protected mice against intestinal inflammation by HFHC induction, suggesting that SC exerts its anti-NASH effects as least in part through intestinal FXR-mediated anti-inflammatory mechanisms.